Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53267
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Type: Journal article
Title: Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects
Author: Guy, B.
Nougarede, N.
Begue, S.
Sanchez, V.
Souag, N.
Carre, M.
Chambonneau, L.
Morrisson, D.
Shaw, D.
Qiao, M.
Dumas, R.
Lang, J.
Forrat, R.
Citation: Vaccine, 2008; 26(45):5712-5721
Publisher: Elsevier Sci Ltd
Issue Date: 2008
ISSN: 0264-410X
1873-2518
Statement of
Responsibility: 
Bruno Guy, Nolwenn Nougarede, Sarah Begue, Violette Sanchez, Nadia Souag, Murielle Carre, Laurent Chambonneau, Dennis N. Morrisson, David Shaw, Ming Qiao, Rafaele Dumas, Jean Lang and Remi Forrat
Abstract: Three independent, phase 1 clinical trials were conducted in Australia and in USA to assess the safety and immunogenicity of sanofi pasteur dengue vaccine candidates. In this context, Dengue 1-4 and Yellow Fever 17D-204 (YF 17D)-specific CD4 and CD8 cellular responses induced by tetravalent chimeric dengue vaccines (CYD) were analyzed in flavivirus-naive or flavivirus-immune patients. Tetravalent CYD vaccine did not trigger detectable changes in serum pro-inflammatory cytokines, whatever the vaccinees immune status, while inducing significant YF 17D NS3-specific CD8 responses and dengue serotype-specific T helper responses. These responses were dominated by serotype 4 in naive individuals, but a booster vaccination (dose #2) performed 4 months following dose #1 broadened serotype-specific responses. A similar, broader response was seen after primary tetravalent immunization in subjects with pre-existing dengue 1 or 2 immunity caused by prior monovalent live-attenuated dengue vaccination. In all three trials, the profile of induced response was similar, whatever the subjects' immune status, i.e. an absence of Th2 response, and an IFN-gamma/TNF-alpha ratio dominated by IFN-gamma, for both CD4 and CD8 responses. Our results also showed an absence of cross-reactivity between YF 17D or Dengue NS3-specific CD8 responses, and allowed the identification of 3 new CD8 epitopes in the YF 17D NS3 antigen. These data are consistent with the previously demonstrated excellent safety of these dengue vaccines in flavivirus-naive and primed individuals.
Keywords: Dengue vaccine; Human; Cellular immunity
RMID: 0020083304
DOI: 10.1016/j.vaccine.2008.08.019
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.